PNC-27
FDA APPROVAL PENDING
Emerging
Longevity
PNC-27
0
Amino acids
Molecular weight
Peptide
Type
PNC-27 is an experimental anti-cancer peptide created by a supercomputer at SUNY Downstate Medical Center in 2000. It contains an HDM-2 binding domain from p53 (residues 12-26) linked to a cell-penetrating domain. The peptide selectively kills cancer cells by binding to HDM-2 (MDM2) expressed on cancer cell membranes, forming pores that cause cell necrosis. Critically, PNC-27 has no effect on normal cells because healthy cells don't express HDM-2 on their membranes. Research shows effectiveness against pancreatic cancer, breast cancer, leukemia, and melanoma.
Top researched benefits
Overview of PNC-27
PNC-27 exploits a unique vulnerability of cancer cells: the presence of HDM-2 (human double minute 2, also called MDM2) on their cell surface. The peptide's p53 residues adopt a conformation that binds directly to membrane-bound HDM-2, inducing transmembrane pore formation. This causes rapid tumor cell necrosis (not apoptosis). Additionally, PNC-27 enters cancer cells and disrupts mitochondrial membranes. Normal cells lack surface HDM-2 expression and are completely spared.
Cancer Research
- PNC-27 shows selective cytotoxicity against pancreatic cancer cells in research.
- Demonstrated effectiveness against breast cancer cell lines.
- Induces necrosis of K-562 leukemia cells through HDM-2 binding.
- Shows selective targeting of melanoma cells.
Mechanism Studies
- Most effective against cancers with high membrane HDM-2 expression.
- Model compound for studying cancer-selective therapies.
Storage
Refrigerate at 2-8°C
Frequency
Research protocols vary by study
Typical Dose
Not established - preclinical research only
Cycle Duration
Not established - no human clinical trials
No visual available
Due to this peptide having no amino acids, there is no molecular chain to display.
Chemical Makeup
Key benefits
Selectively kills cancer cells only
No effect on normal healthy cells
Induces rapid cancer cell necrosis
Works on multiple cancer types
Unique membrane pore mechanism
Does not require p53 function in target cells
Eradicates tumors in mouse models
Spares human stem cells
Community interest
This peptide is still gaining traction in the community.
Anti-Cancer Peptide | p53-HDM-2 Disruptor
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesPNC-27 Molecular Information
View the scientifc details of PNC-27.
Molecular Weight
0DaChain Length
0Amino AcidsType
PeptidePNC-27 Protocols
PNC-27 is currently in preclinical research stages. All dosing data comes from in vitro and animal model studies. No human dosing protocols have been approved. The peptide has shown tumor eradication in nude mice xenograft models.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| Research protocol | — | — | IP or direct tumor injection (research) |
Reconstitution Instructions
Materials needed:
Steps to reconstitute
- Handle as research chemical
- Reconstitute according to research protocol
- Store reconstituted solution refrigerated
- Use appropriate safety precautions
PNC-27 Cycle
The PNC-27 Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
- Week 0-0
- Binding to membrane HDM-2 begins
- Week 0-0
- Pore formation and cancer cell necrosis
- Week 0-0
- Tumor reduction in animal models
- Week 0-0
- Human clinical trials not yet conducted
Dosing tools
PNC-27 Peptide Dosage Calculator
Calculate peptide doses with our visual syringe guide.
0.3mL / 30 units
5 units
0.050 mL
1 mL
2 mL
3 mL
5 mL
Custom
Conversion: 1,000 mcg = 1 mg
Injection Results
Based on your vial and dilution inputs.
Safe concentration range
PNC-27
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg PNC-27 vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
Research Purposes Only
These calculators are provided for educational and research purposes only. Always verify calculations and consult with qualified professionals. The information provided is not medical advice. Peptides should only be used in accordance with applicable laws and regulations.
Reference Guide
Dosing Cycle
- Peptide
- PNC-27
- Dosing
- Not established - preclinical research only
- Dosing Frequency
- Research protocols vary by study
- Cycle Duration
- Not established - no human clinical trials
- Storage
- Refrigerate at 2-8°C
Note: Triple agonist; microdose for fewer side effects
Reconstitution Tips
- Use bacteriostatic water (BAC) — contains 0.9% benzyl alcohol for preservation
- Inject water slowly — aim down the vial wall, not directly onto powder
- Never shake — gently swirl or roll the vial until dissolved
- Store properly — refrigerate at 2-8°C after reconstitution
- Use within 28 days — most reconstituted peptides remain stable for about 4 weeks
- Keep sterile — always clean vial tops with alcohol before drawing
Side effects
Contraindications
Not approved for human use
Experimental research peptide only
Cancers without membrane HDM-2 may not respond
Stop signs
Not applicable - not approved for human use
Bad signs
Comments
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Frequently asked questions
What benefits can peptides offer in research?
Peptides can support cellular repair, immune function, metabolic health, and tissue regeneration. Research suggests they may help with recovery, sleep quality, skin health, and cognitive function, depending on the specific peptide and its mechanism of action.
What are some exciting applications of peptides in modern science?
Current research explores peptides for longevity, muscle recovery, wound healing, metabolic disorders, and neuroprotection. Scientists are also investigating peptide-based drug delivery and targeted therapies that could offer more precise treatment options.
How do peptides influence health and wellness?
Peptides work by binding to receptors on cells and triggering specific biological responses. Depending on the peptide, they may promote growth hormone release, support collagen production, modulate inflammation, or influence neurotransmitter activity—each with different implications for health and wellness.
Where can I find the latest studies on peptide applications?
Peer-reviewed journals such as Nature, Science, and specialized publications like Peptides and the Journal of Peptide Science publish ongoing research. PubMed and Google Scholar are useful for searching studies by peptide name or condition.
Are there any guidelines for using peptides in research?
Research use of peptides typically follows institutional review board (IRB) protocols and regulatory guidelines. Dosage, administration route, and safety monitoring should align with published literature and applicable regulations in your jurisdiction.
What is the difference between peptides and proteins?
Peptides are short chains of amino acids (typically under 50), while proteins are longer chains that fold into complex structures. Peptides are often more stable, easier to synthesize, and can cross cell membranes more readily, making them attractive for therapeutic applications.
How should peptides be stored?
Most peptides require refrigeration (2–8°C) and protection from light. Reconstituted peptides often have shorter stability and may need to be used within days or weeks. Always follow the manufacturer's or research protocol's storage instructions.
Can peptides be taken orally?
Some peptides are bioavailable orally, but many are broken down by digestive enzymes before reaching the bloodstream. Subcutaneous injection, nasal administration, or other routes are often used in research to improve bioavailability. The optimal route depends on the specific peptide.
PNC-27Research References
PNC-27 is an emerging compound
PNC-27
PNC-27 is an emerging compound
Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes
PNC-27 binds membrane-bound HDM-2, inducing pore formation and cancer cell necrosis while sparing normal cells.
n.d.
Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes
PNC-27 also enters cancer cells and disrupts mitochondrial membranes.
n.d.
PNC-27 Induces Tumor Cell Necrosis of Leukemia Cells
PNC-27 induces necrosis of K-562 leukemia cells lacking p53 through p53-independent pathway.
n.d.
PNC-27, a Chimeric p53-Penetratin Peptide
PNC-27 binds HDM-2 in p53 peptide-like structure, induces selective membrane-pore formation leading to cancer cell lysis.
n.d.